Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357291 | 0.93 | EPOR (0.46) | EPORHTR2AALDH1A1SMN1; SMN2MC4R | |
| SCHEMBL7959193 | 0.91 | GAA (0.43) | HTR2AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4391556 | 0.91 | GAA (0.43) | HTR2AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL9692289 | 0.86 | HTR2A (0.37) | EPORHTR2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL7785339 | 0.84 | TPSAB1 (0.47) | EPORTPSAB1TPSD1TPSG1 | |
| SCHEMBL10432184 | 0.82 | MC4R (0.47) | EPORITGA4ITGB7MC4RSSTR3 | |
| SCHEMBL5692891 | 0.82 | EPOR (0.55) | EPORTPSAB1TPSD1TPSG1 | |
| SCHEMBL3820596 | 0.82 | TPSAB1 (0.53) | EPORTPSAB1TPSD1TPSG1 | |
| SCHEMBL4150947 | 0.82 | TPSAB1 (0.53) | EPORTPSAB1TPSD1TPSG1 | |
| SCHEMBL375887 | 0.82 | TPSAB1 (0.53) | EPORTPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195641-B | Sulfoxonium ylide derivatives as probes for cysteine proteases | 武田药品工业株式会社 | 2024-09-03 | — | — | CN | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | CTSZ, CTSF, CTSL | EPOR 4381/4885HTR2A 4358/4885TPSAB1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.